The possibility of India getting a fourth ‘weapon’ against Corona has been strengthened. Ahmedabad-based pharmaceutical company Zydus Cadila is likely to apply for approval for emergency use of its Kovid-19 vaccine ‘ZyCoV-D’ in India this month. The company is confident that the vaccine will be approved in May itself. The company is claiming production of 10 million Corona vaccines per month.
According to an India Today report, if approved, ZyCoV-D will be the fourth vaccine to be used in India’s Covid-19 vaccination campaign. Made in India, the company plans to increase vaccine production to 3-4 crore doses per month. It is already in talks with two other manufacturing companies for this.
Intradermal injection can be given in doses
The vaccine should ideally be stored between 2 and 8 ° C. It remains stable even at room temperature at 25 ° C. Its dose is also very easy to apply. The developers have given this information. He says that it can be injected via intradermal injection.
If the emergency use of ZyCoV-D is approved, then the country’s immunization drive will help to overcome the shortfall. Let me tell you that earlier in April, Zydus Cadila announced that his drug Virafin has received a restricted emergency use approval from the Drug Controller General of India for the treatment of mild cases of Covid-19.
Closer to getting approval for emergency use: Sherville Patel
In an interview with India Today TV, Sherville Patel spoke on all aspects of the corona vaccine ZyCoV-D. “Our vaccine is very close to getting emergency use clearance,” he said. “I am very happy to state that India’s first indigenously developed DNA vaccine against Kovid, which is our ZyCoV-D, is very close to approval,” he said.
Children in the age group of 12 to 17 were also included in the vaccine test.
Sharvil Patel said, “We have almost completed all our recruitment for clinical trials. We have, by far, the largest number of patients admitted for a Kovid vaccine trial in India. Part of the trial The number of volunteers vaccinated in the form is 28,000. ” Sharvil Patel also said that his company has also included children in the age group of 12-17 for vaccine testing.
Sherville Patel said that as soon as the efficacy data is received, we will apply to get clearance for emergency use. He said that Zydus Cadila will start producing Kovid-19 vaccines from July as soon as it is approved.
“We expect to see our efficacy figures in mid-May. We expect to produce a good amount of the vaccine,” he said, adding that by May, the company has limited use of the Kovid-19 vaccine. Will be in a position to talk to the regulators.